Effect of tranexamic acid on markers of inflammation in children undergoing craniofacial surgery

Acta Anaesthesiol Scand. 2021 Jan;65(1):34-39. doi: 10.1111/aas.13700. Epub 2020 Sep 29.

Abstract

Background: Tranexamic acid (TXA) reduces blood loss and transfusion requirements during craniosynostosis surgery in small children. Possible interaction from TXA on the inflammatory system is unknown.

Objective: To evaluate the effect of TXA on a wide range of inflammatory markers in children receiving TXA in a randomized, blinded, and placebo controlled study design.

Methods: Thirty children undergoing craniosynostosis surgery with significant blood loss received TXA (bolus dose of 10 mg kg-1 followed by 8 hours continuous infusion of 3 mg kg-1 h-1 ) or placebo in a randomized, double-blinded study design. Using a new proximity extension assays employing a panel of inflammatory biomarkers samples was used for analysis of blood samples obtained pre-operatively, 4 and 24 hours after operation.

Results: Ninety-two inflammatory parameters were measured. TXA did not affect any of the measured parameters as compared with placebo. Among 34 of the 92 pro- and antiinflammatory parameters investigated changes were observed between pre-operative, 4 or 24 hours, respectively, reflecting immune activation during surgical stress.

Conclusion: TXA administration in a low-dose regimen including bolus followed by 8 hours infusion during craniosynostosis surgery did not change any of 92 inflammatory markers as compared with placebo.

Keywords: antifibrinolytic agents; craniosynostoses; fibrinolysis; haemorrhage; inflammation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifibrinolytic Agents*
  • Biomarkers
  • Blood Loss, Surgical / prevention & control
  • Child
  • Double-Blind Method
  • Humans
  • Inflammation / drug therapy
  • Tranexamic Acid*
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents
  • Biomarkers
  • Tranexamic Acid